Market Research Logo

Parkinson’s Disease: Epidemiology Forecast to 2026

Parkinson’s Disease: Epidemiology Forecast to 2026

Summary


Parkinson’s disease (PD) is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s disease, affecting 1-2% of individuals ages 65 years and older worldwide. Parkinson’s disease (PD) is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, as well as non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression (WHO, 2006). Age, genetics, sex, and environmental exposure to pesticides increase the risk of developing PD. Conditions such as depression and anxiety have been identified as comorbidities in Parkinson’s disease (PD).

In the 7MM, the diagnosed prevalent cases of Parkinson’s disease (PD) will increase at an Annual Growth Rate (AGR) of 2.52% per year from 2016 to 2026. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed prevalent cases of Parkinson’s disease (PD) will increase from 1,012,776 cases in 2016 to 1,179,167 cases in 2026, at an AGR of 1.64%. When examining the AGR by individual market, it’s forecasts that all markets will see an increase in the diagnosed prevalent cases of Parkinson’s disease (PD) during the forecast period.

The report Parkinson’s Disease: Epidemiology Forecast to 2026, provides an overview of the risk factors, comorbidities, and global trends for Parkinson’s disease (PD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by age (18 years and older) and sex. The diagnosed prevalent cases are further segmented by Hoehn and Yahr (HY) clinical staging (Stages I, II, III, IV, and V) at diagnosis.

Scope

  • The Parkinson’s Disease Epidemiology Forecast Report provides an overview of the risk factors and global trends of pancreatic cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report provides an overview of the risk factors, comorbidities, and global trends for Parkinson’s disease (PD) in the 7MM. It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of PD segmented by age (18 years and older) and sex. The diagnosed prevalent cases are further segmented by Hoehn and Yahr (HY) clinical staging (Stages I, II, III, IV, and V) at diagnosis.
  • The Parkinson’s disease epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Parkinson’s Disease Epidemiology Forecast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global PD market.
  • Quantify patient populations in the global PD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PD therapeutics in each of the markets covered.
  • Understand magnitude of PD population by clinical stages.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Parkinson’s Disease: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for PD (2016-2026)
3.5.1 Diagnosed Prevalent Cases of PD
3.5.2 Age-Specific Diagnosed Prevalent Cases of PD
3.5.3 Sex-Specific Diagnosed Prevalent Cases of PD
3.5.4 Diagnosed Prevalent Cases of PD by Clinical Staging
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for PD
Table 2: 7MM, Diagnosed Prevalent Cases of PD By Clinical Staging, Both Sexes, Ages ≥18 Years, N, 2016
1.2 List of Figures
Figure 1 7MM, Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, 2016 and 2026
Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of PD, Ages ≥18 Years, 2016
Figure 3: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of PD, 2016-2026
Figure 4: 7MM, Sources Used , Diagnosed Prevalent Cases of PD Clinical Staging, 2016-2026
Figure 5: Diagnosed Prevalent Cases of PD, 7MM, Both Sexes, ≥18 Years, N, 2016
Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, N, 2016
Figure 7: 7MM, Sex-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages ≥18 Years, N, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report